Search Medical Condition
Please enter condition
Please choose location

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (305) clinical trials

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Phase

NeuroTrials Research is conducting a study to examine the effect of an investigational drug on sleep quality in patients with mild Alzheimer's Disease and cognitive impairment. All study-related care and study drug will be provided at no cost. Qualified participants and caregivers will be compensated for time and travel. Patient ...

Phase

52 week duration Lab testing physical exams mental scales PET and MRI scans

Phase

A Phase III, Randomized, Placebo-Controlled, Double Blind Clinical Trial to study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment (aMCI) due to Alzheimer’s Disease (prodromal AD).M

Phase N/A

Dementia Clinical Trial

Phase

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.

Phase

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

A Study Evaluating RVT-101 in Subjects with Dementia with Lewy Bodies: Study Design: A double-blind, randomized, placebo-controlled study in 240 individuals with a diagnosis of dementia with Lewy bodies Total participation in the study will be about 32 weeks, including the screening period Stable background therapy will be allowed Following ...

Phase

Eli Lilly and Company (Lilly) is developing LY3202626, a synthetic small molecule which is a potent inhibitor of β-site amyloid precursor protein (APP)-cleaving enzyme [BACE]1, for the treatment of Alzheimer’s disease (AD). It is hypothesized that inhibition of BACE1 may slow or inhibit the progression of AD. Study I7X-MC-LLCF (LLCF), ...

Phase